1.77
Vigil Neuroscience Inc stock is traded at $1.77, with a volume of 131.49K.
It is up +5.36% in the last 24 hours and down -26.86% over the past month.
See More
Previous Close:
$1.68
Open:
$1.67
24h Volume:
131.49K
Relative Volume:
0.14
Market Cap:
$78.41M
Revenue:
-
Net Income/Loss:
$-82.60M
P/E Ratio:
-0.8592
EPS:
-2.06
Net Cash Flow:
$-48.61M
1W Performance:
-1.67%
1M Performance:
-26.86%
6M Performance:
-47.94%
1Y Performance:
-46.77%
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Name
Vigil Neuroscience Inc
Sector
Industry
Phone
857-254-4445
Address
100 FORGE ROAD, WATERTOWN
Compare VIGL with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
VIGL
Vigil Neuroscience Inc
|
1.77 | 78.41M | 0 | -82.60M | -48.61M | -2.06 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-04-24 | Initiated | William Blair | Outperform |
Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Oct-18-23 | Initiated | JMP Securities | Mkt Outperform |
Mar-31-23 | Initiated | Mizuho | Buy |
Sep-16-22 | Initiated | Wedbush | Outperform |
Aug-29-22 | Initiated | H.C. Wainwright | Buy |
Feb-01-22 | Initiated | Guggenheim | Buy |
Feb-01-22 | Initiated | Jefferies | Buy |
Feb-01-22 | Initiated | Morgan Stanley | Equal-Weight |
Feb-01-22 | Initiated | Stifel | Buy |
View All
Vigil Neuroscience Inc Stock (VIGL) Latest News
Vigil Neuroscience advances Alzheimer’s drug into Phase 2 trials - Investing.com India
Vigil presents data on oral small molecule program including VG-3927 - TipRanks
Vigil Neuroscience advances Alzheimer’s drug into Phase 2 trials By Investing.com - Investing.com Australia
Vigil Neuroscience Presents Data on its Small Molecule - GlobeNewswire
Clinical Data Breakthrough: Vigil's New Alzheimer's Drug Targets Both Aβ and Tau Pathologies - Stock Titan
Vigil Neuroscience Reports 2024 Results and Clinical Progress - TipRanks
Vigil Neuroscience Files Secondary Stock Shelf - MarketScreener
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Large Decline in Short Interest - Defense World
Vigil Neuroscience (VIGL) to Release Earnings on Tuesday - Defense World
H.C. Wainwright cuts Vigil Neuroscience stock target to $14 By Investing.com - Investing.com Canada
Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
H.C. Wainwright cuts Vigil Neuroscience stock target to $14 - Investing.com India
FY2029 Earnings Forecast for VIGL Issued By Wedbush - Defense World
Q1 Earnings Estimate for VIGL Issued By William Blair - Defense World
HC Wainwright Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price - Defense World
Wedbush Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price - Defense World
Vigil Neuroscience Inc.: Promising Biomarker Data and Strategic Advancements Justify Buy Rating - TipRanks
Wedbush Cuts Price Target on Vigil Neuroscience to $13 From $24, Keeps Outperform Rating - Marketscreener.com
Stifel maintains Buy on Vigil Neuroscience, target at $11 By Investing.com - Investing.com Australia
Vigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share Dilution - TipRanks
Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data By Investing.com - Investing.com South Africa
Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data - Investing.com
Stifel maintains Buy on Vigil Neuroscience, target at $11 - Investing.com
Vigil Neuroscience, Inc. SEC 10-K Report - TradingView
Vigil Neuroscience, Inc. Reports Positive Phase 1 Data for VG-3927 and Outlines Upcoming Milestones in Alzheimer’s Disease and ALSP Treatment Programs - Nasdaq
Vigil Neuroscience, Inc. Loss At -$23.83 Mln In Q4 - Nasdaq
Vigil Neuroscience Reports Fourth Quarter and Full Year - GlobeNewswire
Vigil's Alzheimer's Drug Shows 50% Brain Biomarker Reduction in Phase 1 Success - StockTitan
SPY ETF News, 3/13/2025 - The Globe and Mail
Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum - GlobeNewswire
Vigil Neuroscience To Present At The Stifel 2025 Virtual CNS Forum - MENAFN.COM
Exclusive CNS Forum: Vigil Neuroscience Reveals Latest Breakthroughs in Neurodegeneration Treatment - StockTitan
Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely? - Yahoo Finance
Best Stock to Buy Right Now: Dutch Bros vs. Starbucks - The Globe and Mail
Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Drops By 43.6% - Defense World
Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025 - Insider Monkey
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - PR Newswire
What Did We Find About Insider Trading At Vigil Neuroscience Inc (NASDAQ: VIGL)? - Stocks Register
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial - MSN
Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 145.8% - MarketBeat
abrdn plc Purchases 293,461 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
VIGLVigil Neuroscience, Inc. Latest Stock News & Market Updates - StockTitan
VIGL Stock Update: Vigil Neuroscience Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
The Attractiveness of Investing In Vigil Neuroscience Inc (VIGL) is Growing - Knox Daily
Are Vigil Neuroscience Inc’shares a good deal? - US Post News
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Neurodegenerative Disease Pioneer Vigil to Reveal Latest Developments at Major Biotech Conference - StockTitan
Vigil Neuroscience Reports Positive Data from Phase 1 Clinical Trial on Potential Alzheimer’s Treatment - Defense World
Vigil Neuroscience shares rise on positive Alzheimer's trial data - MSN
Vigil Neuroscience Inc Stock (VIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):